Inhibitor Therapeutics Inc - ESG Rating & Company Profile powered by AI
This webpage displays a free E,S&G report for Inhibitor Therapeutics Inc. Alternative corporations in the scoring industry group for Inhibitor Therapeutics Inc are displayed. The analysis of Inhibitor Therapeutics Inc incorporates information from across the internet as well as from available disclosures by Inhibitor Therapeutics Inc.
Inhibitor Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.1; made up of an environmental score of 0.0, social score of 3.2 and governance score of 6.0.
3.1
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1299 | Active Fine Chemicals Ltd | 3.2 | Medium |
1299 | Yuhan Corp | 3.2 | Medium |
1309 | Inhibitor Therapeutics Inc | 3.1 | Medium |
1309 | Champions Oncology Inc | 3.1 | Medium |
1309 | IBEX Technologies Inc | 3.1 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Inhibitor Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Inhibitor Therapeutics Inc disclose current and historical energy intensity?
Does Inhibitor Therapeutics Inc report the average age of the workforce?
Does Inhibitor Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Inhibitor Therapeutics Inc disclose its ethnicity pay gap?
Does Inhibitor Therapeutics Inc disclose cybersecurity risks?
Does Inhibitor Therapeutics Inc offer flexible work?
Does Inhibitor Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Inhibitor Therapeutics Inc disclose the number of employees in R&D functions?
Does Inhibitor Therapeutics Inc conduct supply chain audits?
Does Inhibitor Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Inhibitor Therapeutics Inc conduct 360 degree staff reviews?
Does Inhibitor Therapeutics Inc disclose the individual responsible for D&I?
Does Inhibitor Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Inhibitor Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Inhibitor Therapeutics Inc disclose water use targets?
Does Inhibitor Therapeutics Inc have careers partnerships with academic institutions?
Did Inhibitor Therapeutics Inc have a product recall in the last two years?
Does Inhibitor Therapeutics Inc disclose incidents of discrimination?
Does Inhibitor Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Inhibitor Therapeutics Inc issued a profit warning in the past 24 months?
Does Inhibitor Therapeutics Inc disclose parental leave metrics?
Does Inhibitor Therapeutics Inc disclose climate scenario or pathway analysis?
Does Inhibitor Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Inhibitor Therapeutics Inc disclose the pay ratio of women to men?
Does Inhibitor Therapeutics Inc support suppliers with sustainability related research and development?
Does Inhibitor Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Inhibitor Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Inhibitor Therapeutics Inc involved in embryonic stem cell research?
Does Inhibitor Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Inhibitor Therapeutics Inc disclose its waste policy?
Does Inhibitor Therapeutics Inc report according to TCFD requirements?
Does Inhibitor Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Inhibitor Therapeutics Inc disclose energy use targets?
Does Inhibitor Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Inhibitor Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Inhibitor Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.